Nicholas Johnson is a Clinical Trials Statistician at Imperial Clinical Trials Unit (ICTU), School of Public Health with over 6 years experience in clinical trials.
Whilst primarily part of the Cardiovascular/Respiratory trial team, he has worked on studies across a number of therapeutic areas. He has also had experience in Phase 1 Pharmacokinetic (PK) analysis. Current studies include; HOPE-HF, DeVENT, MALIBO and RIO whilst past studies include AVATAR-AF, Endobarrier and SERCA-LVAD.
Nicholas completed his BSc in Statistics and Computing from the Open University in 2011 and subsequently obtained an MSc (Merit) in Statistics from the University of Kent in 2013.
A keen runner and cat-lover, Nicholas has been with ICTU since October 2015.
et al., 2022, The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial, Trials, Vol:23, ISSN:1745-6215
et al., 2022, Duodenal-jejunal bypass liner for the management of Type 2 diabetes and obesity: a multicenter randomized controlled trial, Annals of Surgery, Vol:275, ISSN:0003-4932, Pages:440-447
et al., 2022, Decision support system to evaluate ventilation in the acute respiratory distress syndrome (DeVENT study)-trial protocol, Trials, Vol:23, ISSN:1745-6215, Pages:1-18
et al., 2021, The effect of a duodenal-jejunal bypass liner on lipid profile and blood concentrations of long chain polyunsaturated fatty acids, Clinical Nutrition, Vol:40, ISSN:0261-5614, Pages:2343-2354
et al., 2020, A duodenal sleeve bypass device added to intensive medical therapy for obesity with type 2 diabetes: a RCT, Efficacy and Mechanism Evaluation, Vol:7, ISSN:2050-4365, Pages:1-130